One IVD Reagent Menu, Sixteen COFEPRIS Registrations in Mexico

A laboratory buys an immunoassay analyzer for what it can measure: the instrument is the means, the reagent menu is the product. So when the manufacturer of a closed electrochemiluminescence (ECLIA) platform decided to enter Mexico, its plan followed its commercial logic — register the system, then ship the menu behind it. One submission, one review, one authorization, one launch.

Mexico's registration unit is much smaller than that plan. The same menu ended the program in the Mexican register as sixteen separate registros sanitarios across two risk classes, all held by our Mexican entity. This is how the menu was taken apart, and what sixteen authorizations instead of one demand from the manufacturer that owns them.

The plan assumed a platform; COFEPRIS registers determinations

The registro sanitario is issued per product, and the conditions for putting more than one product on a single registration are narrower than the word "menu" suggests. For diagnostic agents, the grouping criteria in the Supplement for Medical Devices of the Mexican Pharmacopoeia allow reagents, calibrators, controls and buffers to share one registration only when all of them serve the same determination or identification of the same analyte or parameter, under the same analytical method. The general family criteria add the rest of the fence: same manufacturer or its subsidiaries, same distinctive name, same indication or purpose of use.

A platform menu clears the manufacturer test and often the brand test. It fails on purpose of use, because the purpose of a progesterone assay is not the purpose of a tumor-marker assay. What travels inside one registration is the presentation — pack sizes and configurations of the same determination. What does not travel is a second determination. The analyzer sits outside the reagent program entirely: it is equipo médico, a different category with its own file.

That rule sized the program before anything technical was decided: the determination count is the file count, and the file count drives the dossiers, the fees, the labels and, five years on, the renewals. Our first deliverable was an inventory rather than a submission — every item the manufacturer intended to sell, resolved into determinations and presentations against the grouping criteria on our Mexico classification and grouping page.

Two risk classes inside one reagent menu

Classification runs product by product against Annex II of the same Supplement. Edition 5.0, released in 2023, rewrote that ground: Annex II now carries 35 classification rules, and the rules specific to in vitro diagnostic agents grew from four to ten. Class follows what the test is for and what a wrong result would do to the patient, not what instrument runs it.

Applied analyte by analyte, this menu split: the fertility and endocrine hormone assays settled at Clase I, the cardiac markers, tumor markers and control serum at Clase II. One technology and one instrument, but two regulatory populations, with a different official fee band and a different depth of documentation on each side of the line.

An inherited classification memo becomes expensive here, because an assessment written against an earlier edition predates ten IVD rules. We re-ran classification for every item before evidence work began: each file's class sets how much evidence that file carries.

The control serum that could not ride along

The grouping criteria treat control materials separately from the assays they support: products used as external controls are grouped by specialty, not folded into the registration of any one determination. A multi-analyte control serum covering a cardiac panel therefore has nowhere to hide: it is its own diagnostic agent, on its own registration.

Manufacturers meet this in the wrong order, because commercially the control looks like an accessory. Clinically it is not optional: a quantitative menu whose control material is not lawfully on the market is one no accredited laboratory can run under its own quality rules, stranding the assays around it. The control became launch-critical rather than trailing.

The criteria carry a second trap for anyone tempted to pack more into one box: where components are marketed together in one pack, the registered expiry is that of the shortest-dated component, so putting a calibrator inside a kit registration can shorten the shelf life of everything shipped with it.

An evidence spine that sixteen files could share

With the file count fixed, the risk moved to the dossiers, where the trap is symmetrical: sixteen technical files built independently is waste, and sixteen built by copying one is worse, because a performance section carried across analytes contradicts itself in ways a reviewer reads before the writer does. So we split the evidence by what it is actually about. The manufacturing site, the quality system, the platform and measuring principle, the holder documentation and the label architecture belong to the company and the technology, and are genuinely reusable. Intended use, measuring range, precision, interference and cross-reactivity, real-time and in-use stability, and the metrological traceability of values assigned to calibrators and trueness control materials — covered by the Supplement's method MGA-DM 17511 — belong to the analyte, and cannot be inherited from a neighbor on the same instrument.

Two company-level documents then had to be tested against the whole list rather than a representative product. Quality-system evidence accepted in place of a Mexican good-manufacturing-practice certificate — ISO 13485 certification, a CE certificate, or a compliance declaration inside the free-sale certificate — must cover the manufacturing site and production line of each product being registered. The free-sale certificate must identify the products it vouches for clearly enough to match the application, and home-market certificates often name families in local vocabulary or list trade names with no catalog codes. Reconciling both to a sixteen-item list, and having them reissued where they fell short, finished before the first file was built.

One nomenclature, sixteen files

Generic and distinctive names must agree across the application form, the label draft, the free-sale certificate, the power of attorney and the quality-system certificate. Inconsistency between them is among the most ordinary reasons a device file is stopped for correction, and it scales badly: one naming convention applied loosely is sixteen instances of the same defect.

Under Mexico's federal administrative procedure law, the authority may require an applicant to cure omissions in writing and on one occasion, within a term it sets that cannot be shorter than five business days; a term that lapses without a complete answer ends with the file discarded, not merely delayed. Sixteen files each hold one such opportunity, at sixteen different moments.

So one controlled nomenclature table — generic name, distinctive name, catalog code and Spanish wording per item — came before the dossiers and fed every artifact that would quote a product name. Legal documents went to a translator authorized in Mexico, technical translations were endorsed by the responsable sanitario, and discrepancies were corrected at source rather than explained away in a cover letter.

Labels that cannot be finished until the file is granted

Labeling is governed by NOM-137-SSA1-2008. Its successor, NOM-137-SSA1-2025, was published in May 2026 and takes effect on 14 May 2027, with a further 180 days to exhaust existing packaging — so a program entering now builds to the 2008 standard and puts the changeover on the calendar.

Two features of the current rule shape the work. The label design goes in with the registration, for each presentation, and printed labels must match what was approved; and mandatory content includes the registration number issued by the Secretaría de Salud, a number that does not exist until that particular file is granted. Artwork is drafted with a reserved field and completed per product, after each grant, sixteen times.

The rest is scale discipline. One master template carried the Spanish content, the agente de diagnóstico declaration and laboratory-use legend, manufacturer and importer particulars, storage conditions matching each product's stability data, and contents in tests per pack; where original packaging already complied, a Mexican over-label supplied the rest instead of a reprint. And because any change to approved conditions is a filing of its own, one template change reaching the whole menu is sixteen filings. Our Mexico labeling page carries the full content requirements.

Filing the menu in groups rather than all at once

Each file carries its own fee, its own dossier and its own single opportunity to correct, so filing all sixteen at once would concentrate the shared spine's risk into one moment: any weakness in the common documents surfaces in every file simultaneously, with the same short window to answer.

Sequencing was then argued from the clinical side: laboratories adopt a platform for a usable panel, not for a single assay, so a half-registered panel is not a launch. The first group was chosen to complete a clinically coherent panel and to exercise the shared spine on both sides of the class line; the second carried the corrections and confirmed wording forward. The sixteen authorizations came through in two groups rather than one.

Staging controls rework and cash exposure, not speed: grant timing is shaped by queues and authority workload, not by the applicant. The same caution applies to reliance routes, which change the evidence burden without changing the arithmetic. Under the abbreviated route as it now stands, eligibility rests on prior authorization by a regulator of a country on the IMDRF Management Committee, full MDSAP members are recognized for good-manufacturing-practice certificates, and COFEPRIS decides within 30 business days of a complete application. But the binding condition is identity with the version the reference authority approved, and identity is established product by product — a menu qualifies one determination at a time, or not at all.

Sixteen registrations, sixteen calendars

Registrations are issued in the holder's name, and ours holds all sixteen — which keeps modifications, renewals and technovigilance filings in one set of hands and lets distribution beneath the menu change without the authorizations moving. The trade-offs sit on our in-country representation page.

What the program left is a portfolio to operate. Registrations are initially valid for five years, and the January 2026 reform to the General Health Law set renewed authorizations at ten. Renewal is filed ahead of expiry — the 150-natural-day pre-expiry window in Article 190 Bis 7 of the regulation applies specifically to second and subsequent renewals rather than to every filing — and the first extension requires, for each product, the fee, the registration and its modifications, the authorized labels and manuals, and a technovigilance report per product. A complaint and adverse-event process that cannot be sliced by analyte cannot produce sixteen defensible reports. Technovigilance runs on NOM-240, with reporting to CENAFyT under the 2026 health-law reform, as described on our post-market compliance page.

Importation is a separate track. A registration authorizes sale; a COFEPRIS import permit authorizes bringing product in, runs for up to 180 days or a set quantity, is extendable once, and cannot outlast the registration it relies on. On a menu shipping continuously against sixteen registrations with different expiry dates, permits fall due on a rhythm no single registration explains, and the cost of missing one is a laboratory that cannot complete a panel next week.

If your catalog looks like this one

Count determinations before you budget, controls and calibrators included, and expect one menu to occupy more than one class once classification is re-run against the current Supplement. Decide early which evidence belongs to the platform and which to the analyte, and test the free-sale and quality-system certificates against every item. Build the nomenclature and the label master once, then run the result as a portfolio, with renewals, technovigilance reports, import permits and change control each on a named calendar.

Start with the Mexico market page or our IVD page, price a menu with the fee calculator, or talk to our team about the catalog you want to register.